Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)
Stopped early · Phase 1/Phase 2
Conditions studied: Acute Myeloid Leukemia
In brief
This study will evaluate the efficacy, safety, and tolerability of entospletinib when administered as monotherapy or in combination with chemotherapy in adults with acute myeloid leukemia (AML).
Key facts
- Study ID
- NCT02343939
- Run by
- Gilead Sciences
- People needed
- 148
- Starts
- 2015-07-01
- Expected to finish
- 2019-02-21
- Last updated by the study team
- 2019-11-15
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- UCLA — Los Angeles, California, United States
- University of Chicago — Chicago, Illinois, United States
- Loyola University Medical Center — Maywood, Illinois, United States
- Indiana University — Indianapolis, Indiana, United States
- University of Kansas Medical Center Research Institute, Inc — Fairway, Kansas, United States
- Dana Farber Cancer Institute — Boston, Massachusetts, United States
- Henry Ford Health System — Detroit, Michigan, United States
- Karmanos Cancer Institute — Detroit, Michigan, United States
- Weill Cornell Medical College - New York - Presbyterian Hospital — New York, New York, United States
- Duke Cancer Center — Durham, North Carolina, United States
- University Hospitals Case Medical Center — Cleveland, Ohio, United States
- Ohio State University — Columbus, Ohio, United States
- Oregon Health & Science University — Portland, Oregon, United States
- Saint Francis Cancer Center — Greenville, South Carolina, United States
- Princess Margaret — Toronto, Ontario, Canada
- Jewish General Hospital — Montreal, Quebec, Canada
- Universitätsklinikum Frankfurt Medizinische Klinik II — Frankfurt, Germany
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.